Marcia Simpson Brose, MD PhD
Assistant Professor of Otorhinolaryngology: Head and Neck Surgery
Member, University of Pennsylvania Center for Research on Reproduction and Women’s Health
Member, Abramson Cancer Center of the University of Pennsylvania
Director Head and Neck Clinical Trials, Department of Otorhinolaryngology: Head and Neck Surgery
Director, Thyroid Cancer Theraputics Program, Department of Otorhinolaryngolgy: Head and Neck Surgery
Vice Chair, Clinical Trials Scientific Review and Monitoring Committee (CTSRMC), Abramson Cancer Center
Department: Otorhinolaryngology: Head and Neck Surgery
Contact information
Clinical Research Building (CRB), Room 127
415 Curie Blvd.
Philadelphia, PA 19104
415 Curie Blvd.
Philadelphia, PA 19104
Office: 215-746-6344
Fax: 215-573-1934
Fax: 215-573-1934
Email:
brosem@mail.med.upenn.edu
brosem@mail.med.upenn.edu
Graduate Group Affiliations
Publications
Links
Search PubMed for articles
Primary Work Website
PUBMED link
Otorhinolaryngology Department Home Page
Search PubMed for articles
Primary Work Website
PUBMED link
Otorhinolaryngology Department Home Page
Education:
B.A. (Biology)
Amherst College, Amherst, MA, 1986.
Ph.D. (Genetics and Developmental Biology)
Rockefeller University, New York, NY, 1994.
M.D. (Medicine)
Cornell University Medical College, New York, NY, 1995.
B.A. (Biology)
Amherst College, Amherst, MA, 1986.
Ph.D. (Genetics and Developmental Biology)
Rockefeller University, New York, NY, 1994.
M.D. (Medicine)
Cornell University Medical College, New York, NY, 1995.
Post-Graduate Training
Intern in Medicine, Hospital of the University of Pennsylvania, 1995-1996.
Resident in Medicine, Hospital of the University of Pennsylvania, 1996-1997.
Fellowship in Hematology/Oncology, Hospital of the University of Pennsylvania, 1997-2001.
Post-doctoral Research in Cancer Genetics, University of Pennsylvania Cancer Center, Laborartory of Barbara Weber MD, 1998-2001.
Fellow/Trainee, University of Pennsylvania, Patient Oriented Research Training Program , 1998-1999.
Intern in Medicine, Hospital of the University of Pennsylvania, 1995-1996.
Resident in Medicine, Hospital of the University of Pennsylvania, 1996-1997.
Fellowship in Hematology/Oncology, Hospital of the University of Pennsylvania, 1997-2001.
Post-doctoral Research in Cancer Genetics, University of Pennsylvania Cancer Center, Laborartory of Barbara Weber MD, 1998-2001.
Fellow/Trainee, University of Pennsylvania, Patient Oriented Research Training Program , 1998-1999.
Certifications
American Board of Internal Medicine, 1998.
Subspecialty Boards in Oncology, 2003.
Permanent linkAmerican Board of Internal Medicine, 1998.
Subspecialty Boards in Oncology, 2003.
Description of Research Expertise
Dr Brose runs a lab in the field of tranlsational studies in cancer genetics and genomics. Dr. Brose’s basic science research interest involves the identification of genetic abnormalities in the tumors of patients undergoing targeted therapies. She currently has projects underway in thyroid cancer, breast cancer, lung cancer, colon cancer and esophageal cancer. Once identified, she is interested in understanding if these changes may identify tumors that may have or lack resistance to certain compounds. She has experience in the use of mice, drosophila, human tissue culture and clincial tissue samples. Her analytic tools include all types of PCR, RT-PCR, as well as the use of array comparative genomic hybridization (aCGH) and transcription profiling, taqman analysis, Q-RT-PCR and DNA sequencing on a regular basis. She also uses high resolution expression and SNP genotyping tetchnologies (Affymetrix and Illumina) to study the genetic basis of cancer. Dr. Brose provides the key correlative science for ongoing phaseI/II/III clinical trials at the University and internationally.Description of Clinical Expertise
Familial cancer syndromes and cancer risk evaluation, PhaseI/II clinical trials, novel drug target discovery, and use of genetic testing in diagnosis, prognostication and treatment of cancer. Treatment of advanced thyroid cancer and cancers of the head and neck, lung and esophagus.Description of Other Expertise
Teaches residents and medical student who rotate through her lab in Hematology/Oncology and Cell geneticsSelected Publications
Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G,Chung J, Kalmus J, Kappeler C, Schlumberger M: Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)–refractory, differentiated thyroid cancer. BMC Cancer 11: 349, August 2011.DiRienzo, Joseph; Damek-Poprawa, Monika; Volgina, Alla; Korostoff, Jonathan; Sollecito, Thomas P; Brose, Marcia S; O'Malley, Jr, Bert W; Akintoye, Sunday : Targeted Inhibition of CD133+ Cells in Oral Cancer Cell Lines Journal of Dental Research 90(5), January 2011.
Neely R.J., Brose M.S., Gray C.M., McCorkell K.A., Leibowitz J.M., Ma C., Rothstein J.L., May M.J.: The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIK. Oncogene, Epub 2010 Sep 6. (eds.). 30(1): 87-96, Jan 2011.
Tsygankova, O.M., Ma, C., Tang, W., Korch, C. , Feldman, M.D., Yu Lv, Brose, M.S. and Meinkoth, J.L. (Dr. Brose is a co-senior author for this manuscript): Downregulation of Rap1GAP in human tumor cells alters cell/1 matrix and cell/cell adhesion. Molecular and Cellular Biology 30(13): 3262-74, July (epub May 3 ahead of print) 2010 Notes: Cover Art for journal provided from Dr. Brose's laboratory.
Brose, Marcia S.: Thyroid Cancer Update. Conversations with Oncology Investigators, Research to Practice. Neil Love MD (eds.). 3(1), October 2010 Notes: CME acredited activity/PODcast Distributed to Practicing Medical Oncologist across the US.
Brose M.S., Nutting,C.N., Shermann,S.I., Shong Y.K.,Smit, J.W.A., Reike, G., Chung,J.,Kalmus, J., Kappeler. C., Schlumberger, M. : Rationale and Design of DECISION: a Phase III Trial Evaluating the Efficacy and Safety of Sorafenib in Patients with Locally Advanced or Metastatic, Radioactive Iodine (RAI)–Refractory, Differentiated Thyroid Cancer. (Oral abstract presentation) Proceedings of the International Thyroid Congress 2010 September 2010.
Gombos Z, Danihel L, Puttaswamy K, Brose M: A comparative study of EGFR mutation screening methods in non-small cell carcinoma of lung. Bratislavské lekárske listy 111(7): 365-8, August 2010.
Keefe S.M., Cohen M.A., Brose M.S.: Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. Clinical Cancer Research 16(3): 778-83, Feb 2010.
Dougherty M.J., Santi M., Brose M.S., Ma C., Resnick A.C., Sievert A.J., Storm P.B., Biegel J.A.: Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro-oncology 12(7): 621-630, Feb 2010.
Flaherty KT, Brose MS. : Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment. Clin Cancer Res. 2009 Dec 15;15(24):7749. 15(24): 7749, December 2009.
